Click here to get full coverage on Ring, chief legal officer, sells Nurix (NRIX) shares for $125,792 - Investing.com

Ring, chief legal officer, sells Nurix (NRIX) shares for $125,792  Investing.com

Ring, chief legal officer, sells Nurix (NRIX) shares for $125,792 - Investing.com

Click here to get full coverage on Handelsbanken Fonder AB Buys 240,000 Shares of Nurix Therapeutics, Inc. $NRIX - MarketBeat

Handelsbanken Fonder AB Buys 240,000 Shares of Nurix Therapeutics, Inc. $NRIX  MarketBeat

Handelsbanken Fonder AB Buys 240,000 Shares of Nurix Therapeutics, Inc. $NRIX - MarketBeat

Click here to get full coverage on Nurix Therapeutics (NRIX) Valuation Check After Recent Share Price Volatility And Rich Price To Sales Multiple - Yahoo Finance

Nurix Therapeutics (NRIX) Valuation Check After Recent Share Price Volatility And Rich Price To Sales Multiple  Yahoo Finance

Nurix Therapeutics (NRIX) Valuation Check After Recent Share Price Volatility And Rich Price To Sales Multiple - Yahoo Finance

Click here to get full coverage on Insider Sell: Christine Ring Sells Shares of Nurix Therapeutics Inc (NRIX) - GuruFocus

Insider Sell: Christine Ring Sells Shares of Nurix Therapeutics Inc (NRIX)  GuruFocus

Insider Sell: Christine Ring Sells Shares of Nurix Therapeutics Inc (NRIX) - GuruFocus

Click here to get full coverage on Avoiding Lag: Real-Time Signals in (NRIX) Movement - Stock Traders Daily

Avoiding Lag: Real-Time Signals in (NRIX) Movement  Stock Traders Daily

Avoiding Lag: Real-Time Signals in (NRIX) Movement - Stock Traders Daily

Click here to get full coverage on Baker Bros discloses 7.2% Nurix (NRIX) ownership stake - Stock Titan

Baker Bros discloses 7.2% Nurix (NRIX) ownership stake  Stock Titan

Baker Bros discloses 7.2% Nurix (NRIX) ownership stake - Stock Titan

Click here to get full coverage on Nurix Therapeutics, Inc. $NRIX Stock Position Increased by Amova Asset Management Americas Inc. - MarketBeat

Nurix Therapeutics, Inc. $NRIX Stock Position Increased by Amova Asset Management Americas Inc.  MarketBeat

Nurix Therapeutics, Inc. $NRIX Stock Position Increased by Amova Asset Management Americas Inc. - MarketBeat

Click here to get full coverage on Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock Rockets 30% As Investors Are Less Pessimistic Than Expected - simplywall.st

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock Rockets 30% As Investors Are Less Pessimistic Than Expected  simplywall.st

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock Rockets 30% As Investors Are Less Pessimistic Than Expected - simplywall.st

Click here to get full coverage on Needham Reiterates Nurix Therapeutics (NRIX) Buy Recommendation - Nasdaq

Needham Reiterates Nurix Therapeutics (NRIX) Buy Recommendation  Nasdaq

Needham Reiterates Nurix Therapeutics (NRIX) Buy Recommendation - Nasdaq

Click here to get full coverage on Nurix Therapeutics, Inc. (NRIX) Price Target Trimmed After Q3 Miss, Buy Rating Reaffirmed - Yahoo Finance

Nurix Therapeutics, Inc. (NRIX) Price Target Trimmed After Q3 Miss, Buy Rating Reaffirmed  Yahoo Finance

Nurix Therapeutics, Inc. (NRIX) Price Target Trimmed After Q3 Miss, Buy Rating Reaffirmed - Yahoo Finance

Click here to get full coverage on Assessing Nurix Therapeutics (NRIX) Valuation After Revenue Growth Wider Loss And New Shelf Registration - simplywall.st

Assessing Nurix Therapeutics (NRIX) Valuation After Revenue Growth Wider Loss And New Shelf Registration  simplywall.st

Assessing Nurix Therapeutics (NRIX) Valuation After Revenue Growth Wider Loss And New Shelf Registration - simplywall.st

Click here to get full coverage on ARK Investment Management LLC Has $13.96 Million Position in Nurix Therapeutics, Inc. $NRIX - MarketBeat

ARK Investment Management LLC Has $13.96 Million Position in Nurix Therapeutics, Inc. $NRIX  MarketBeat

ARK Investment Management LLC Has $13.96 Million Position in Nurix Therapeutics, Inc. $NRIX - MarketBeat

Click here to get full coverage on Nurix Therapeutics (NRIX): Revisiting Valuation After a 120% Three-Month Share Price Surge - Yahoo Finance

Nurix Therapeutics (NRIX): Revisiting Valuation After a 120% Three-Month Share Price Surge  Yahoo Finance

Nurix Therapeutics (NRIX): Revisiting Valuation After a 120% Three-Month Share Price Surge - Yahoo Finance

Click here to get full coverage on Nurix (NRIX) Soars 18.7% on Encouraging Blood Cancer Treatment Trial - Yahoo Finance

Nurix (NRIX) Soars 18.7% on Encouraging Blood Cancer Treatment Trial  Yahoo Finance

Nurix (NRIX) Soars 18.7% on Encouraging Blood Cancer Treatment Trial - Yahoo Finance

Click here to get full coverage on H.C. Wainwright Remains a Buy on Nurix Therapeutics (NRIX) - Yahoo Finance

H.C. Wainwright Remains a Buy on Nurix Therapeutics (NRIX)  Yahoo Finance

H.C. Wainwright Remains a Buy on Nurix Therapeutics (NRIX) - Yahoo Finance

Click here to get full coverage on Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance

Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Misses Revenue Estimates  Yahoo Finance

Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance

Click here to get full coverage on Assessing Nurix Therapeutics (NRIX) Valuation After Recent Share Price Volatility - Yahoo Finance

Assessing Nurix Therapeutics (NRIX) Valuation After Recent Share Price Volatility  Yahoo Finance

Assessing Nurix Therapeutics (NRIX) Valuation After Recent Share Price Volatility - Yahoo Finance

Click here to get full coverage on Nurix Therapeutics (NRIX) Is Down 7.4% After Wider 2025 Losses And New ESOP Share Shelf - What's Changed - Yahoo Finance

Nurix Therapeutics (NRIX) Is Down 7.4% After Wider 2025 Losses And New ESOP Share Shelf - What's Changed  Yahoo Finance

Nurix Therapeutics (NRIX) Is Down 7.4% After Wider 2025 Losses And New ESOP Share Shelf - What's Changed - Yahoo Finance

Click here to get full coverage on Stifel Raised Nurix Therapeutics, Inc. (NRIX) Price Target to $35 and Maintains Buy Ahead of 2026 Catalysts - Yahoo Finance

Stifel Raised Nurix Therapeutics, Inc. (NRIX) Price Target to $35 and Maintains Buy Ahead of 2026 Catalysts  Yahoo Finance

Stifel Raised Nurix Therapeutics, Inc. (NRIX) Price Target to $35 and Maintains Buy Ahead of 2026 Catalysts - Yahoo Finance

Click here to get full coverage on Wells Fargo Reaffirms a Buy Rating on Nurix Therapeutics (NRIX), Sets a $30 PT - Yahoo Finance

Wells Fargo Reaffirms a Buy Rating on Nurix Therapeutics (NRIX), Sets a $30 PT  Yahoo Finance

Wells Fargo Reaffirms a Buy Rating on Nurix Therapeutics (NRIX), Sets a $30 PT - Yahoo Finance

Click here to get full coverage on Nurix Therapeutics (NRIX): Losses Worsen 21.7% Annually, Reinforcing Profitability Concerns Despite Growth Narrative - Yahoo Finance

Nurix Therapeutics (NRIX): Losses Worsen 21.7% Annually, Reinforcing Profitability Concerns Despite Growth Narrative  Yahoo Finance

Nurix Therapeutics (NRIX): Losses Worsen 21.7% Annually, Reinforcing Profitability Concerns Despite Growth Narrative - Yahoo Finance

Click here to get full coverage on Nurix Therapeutics, Inc. (NRIX): Biotechnology Innovator With 86% Potential Upside - DirectorsTalk Interviews

Nurix Therapeutics, Inc. (NRIX): Biotechnology Innovator With 86% Potential Upside  DirectorsTalk Interviews

Nurix Therapeutics, Inc. (NRIX): Biotechnology Innovator With 86% Potential Upside - DirectorsTalk Interviews

Click here to get full coverage on $NRIX stock is up 19% today. Here's what we see in our data. - Quiver Quantitative

$NRIX stock is up 19% today. Here's what we see in our data.  Quiver Quantitative

$NRIX stock is up 19% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Misses Revenue Estimates - Nasdaq

Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Misses Revenue Estimates  Nasdaq

Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Misses Revenue Estimates - Nasdaq

Click here to get full coverage on Nurix Therapeutics (NRIX) Q4 Loss Highlights Ongoing Profitability Concerns Despite Revenue Progress - simplywall.st

Nurix Therapeutics (NRIX) Q4 Loss Highlights Ongoing Profitability Concerns Despite Revenue Progress  simplywall.st

Nurix Therapeutics (NRIX) Q4 Loss Highlights Ongoing Profitability Concerns Despite Revenue Progress - simplywall.st

Click here to get full coverage on Assessing Nurix Therapeutics (NRIX) Valuation After Revenue Growth Wider Loss And New Shelf Registration - Sahm

Assessing Nurix Therapeutics (NRIX) Valuation After Revenue Growth Wider Loss And New Shelf Registration  Sahm

Assessing Nurix Therapeutics (NRIX) Valuation After Revenue Growth Wider Loss And New Shelf Registration - Sahm

Click here to get full coverage on Nurix Therapeutics (Nasdaq: NRIX) fireside chat at Piper Sandler 37th conference - Stock Titan

Nurix Therapeutics (Nasdaq: NRIX) fireside chat at Piper Sandler 37th conference  Stock Titan

Nurix Therapeutics (Nasdaq: NRIX) fireside chat at Piper Sandler 37th conference - Stock Titan

Click here to get full coverage on Nurix Therapeutics, Inc. (NASDAQ:NRIX) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year - simplywall.st

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year  simplywall.st

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year - simplywall.st

Click here to get full coverage on What Nurix Therapeutics (NRIX)'s Phase 2 NX-5948 Trial Launch Means For Shareholders - Yahoo Finance

What Nurix Therapeutics (NRIX)'s Phase 2 NX-5948 Trial Launch Means For Shareholders  Yahoo Finance

What Nurix Therapeutics (NRIX)'s Phase 2 NX-5948 Trial Launch Means For Shareholders - Yahoo Finance

Click here to get full coverage on Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Consensus Rating of "Moderate Buy" from Brokerages  MarketBeat

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Click here to get full coverage on Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation - simplywall.st

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation  simplywall.st

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation - simplywall.st

Click here to get full coverage on Nurix Therapeutics: Why This Company Could Double In Value? (NASDAQ:NRIX) - Seeking Alpha

Nurix Therapeutics: Why This Company Could Double In Value? (NASDAQ:NRIX)  Seeking Alpha

Nurix Therapeutics: Why This Company Could Double In Value? (NASDAQ:NRIX) - Seeking Alpha

Click here to get full coverage on We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully - Yahoo Finance

We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully  Yahoo Finance

We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully - Yahoo Finance

Click here to get full coverage on Discipline and Rules-Based Execution in NRIX Response - Stock Traders Daily

Discipline and Rules-Based Execution in NRIX Response  Stock Traders Daily

Discipline and Rules-Based Execution in NRIX Response - Stock Traders Daily

Click here to get full coverage on Insider Sale: Chief Legal Officer of $NRIX Sells 37,600 Shares | NRIX Stock News - Quiver Quantitative

Insider Sale: Chief Legal Officer of $NRIX Sells 37,600 Shares | NRIX Stock News  Quiver Quantitative

Insider Sale: Chief Legal Officer of $NRIX Sells 37,600 Shares | NRIX Stock News - Quiver Quantitative

Click here to get full coverage on Nurix Therapeutics (NRIX) Is Down 7.4% After Pivotal Bexobrutideg Update and Wider 2025 Loss - simplywall.st

Nurix Therapeutics (NRIX) Is Down 7.4% After Pivotal Bexobrutideg Update and Wider 2025 Loss  simplywall.st

Nurix Therapeutics (NRIX) Is Down 7.4% After Pivotal Bexobrutideg Update and Wider 2025 Loss - simplywall.st

Click here to get full coverage on Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher - simplywall.st

Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher  simplywall.st

Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher - simplywall.st

Click here to get full coverage on New Analyst Forecast: $NRIX Given $26 Price Target - Quiver Quantitative

New Analyst Forecast: $NRIX Given $26 Price Target  Quiver Quantitative

New Analyst Forecast: $NRIX Given $26 Price Target - Quiver Quantitative

Click here to get full coverage on 49.3% disease control rate: Nurix’s NX-1607 shows monotherapy activity and a confirmed PR in MSS CRC - Stock Titan

49.3% disease control rate: Nurix’s NX-1607 shows monotherapy activity and a confirmed PR in MSS CRC  Stock Titan

49.3% disease control rate: Nurix’s NX-1607 shows monotherapy activity and a confirmed PR in MSS CRC - Stock Titan

Click here to get full coverage on NRIX: Bexobrutideg achieved a 75% response rate with durable, well-tolerated outcomes in Waldenström macroglobulinemia - TradingView

NRIX: Bexobrutideg achieved a 75% response rate with durable, well-tolerated outcomes in Waldenström macroglobulinemia  TradingView

NRIX: Bexobrutideg achieved a 75% response rate with durable, well-tolerated outcomes in Waldenström macroglobulinemia - TradingView

Click here to get full coverage on Nurix Therapeutics (Nasdaq: NRIX) to host Dec. 8 webcast on Phase 1 bexobrutideg CLL data - Stock Titan

Nurix Therapeutics (Nasdaq: NRIX) to host Dec. 8 webcast on Phase 1 bexobrutideg CLL data  Stock Titan

Nurix Therapeutics (Nasdaq: NRIX) to host Dec. 8 webcast on Phase 1 bexobrutideg CLL data - Stock Titan

Click here to get full coverage on $NRIX stock is up 7% today. Here's what we see in our data. - Quiver Quantitative

$NRIX stock is up 7% today. Here's what we see in our data.  Quiver Quantitative

$NRIX stock is up 7% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Nurix Therapeutics (NRIX) Announces $250 Million Share Offering - GuruFocus

Nurix Therapeutics (NRIX) Announces $250 Million Share Offering  GuruFocus

Nurix Therapeutics (NRIX) Announces $250 Million Share Offering - GuruFocus

Click here to get full coverage on NRIX: Morgan Stanley Upgrades Nurix Therapeutics with a Raised P - GuruFocus

NRIX: Morgan Stanley Upgrades Nurix Therapeutics with a Raised P  GuruFocus

NRIX: Morgan Stanley Upgrades Nurix Therapeutics with a Raised P - GuruFocus

Click here to get full coverage on Why Nurix Therapeutics (NRIX) Is Among the Best Low Priced Biotech Stocks to Buy Now - Yahoo Finance

Why Nurix Therapeutics (NRIX) Is Among the Best Low Priced Biotech Stocks to Buy Now  Yahoo Finance

Why Nurix Therapeutics (NRIX) Is Among the Best Low Priced Biotech Stocks to Buy Now - Yahoo Finance

Click here to get full coverage on Nurix Therapeutics, Inc. (NRIX): A Bull Case Theory - Insider Monkey

Nurix Therapeutics, Inc. (NRIX): A Bull Case Theory  Insider Monkey

Nurix Therapeutics, Inc. (NRIX): A Bull Case Theory - Insider Monkey

Click here to get full coverage on Nurix Therapeutics: Clinical Wins Offer Asymmetric Upside (NASDAQ:NRIX) - Seeking Alpha

Nurix Therapeutics: Clinical Wins Offer Asymmetric Upside (NASDAQ:NRIX)  Seeking Alpha

Nurix Therapeutics: Clinical Wins Offer Asymmetric Upside (NASDAQ:NRIX) - Seeking Alpha

Click here to get full coverage on New Analyst Forecast: $NRIX Given $32 Price Target - Quiver Quantitative

New Analyst Forecast: $NRIX Given $32 Price Target  Quiver Quantitative

New Analyst Forecast: $NRIX Given $32 Price Target - Quiver Quantitative

Click here to get full coverage on Ring Christine, chief legal officer at Nurix, sells $237k in NRIX stock - Investing.com Nigeria

Ring Christine, chief legal officer at Nurix, sells $237k in NRIX stock  Investing.com Nigeria

Ring Christine, chief legal officer at Nurix, sells $237k in NRIX stock - Investing.com Nigeria

Click here to get full coverage on NRIX: Advanced pivotal CLL trials, grew revenue, and maintained strong cash reserves - TradingView

NRIX: Advanced pivotal CLL trials, grew revenue, and maintained strong cash reserves  TradingView

NRIX: Advanced pivotal CLL trials, grew revenue, and maintained strong cash reserves - TradingView

Click here to get full coverage on NRIX: Mizuho Raises Price Target, Maintains Outperform Rating | - GuruFocus

NRIX: Mizuho Raises Price Target, Maintains Outperform Rating |  GuruFocus

NRIX: Mizuho Raises Price Target, Maintains Outperform Rating | - GuruFocus

Click here to get full coverage on Nurix Therapeutics (NRIX) Stock Soars on ASH 2025 Trial Data: Latest News, Analyst Forecasts and Outlook as of December 8, 2025 - TechStock²

Nurix Therapeutics (NRIX) Stock Soars on ASH 2025 Trial Data: Latest News, Analyst Forecasts and Outlook as of December 8, 2025  TechStock²

Nurix Therapeutics (NRIX) Stock Soars on ASH 2025 Trial Data: Latest News, Analyst Forecasts and Outlook as of December 8, 2025 - TechStock²

Click here to get full coverage on New Analyst Forecast: $NRIX Given $36 Price Target - Quiver Quantitative

New Analyst Forecast: $NRIX Given $36 Price Target  Quiver Quantitative

New Analyst Forecast: $NRIX Given $36 Price Target - Quiver Quantitative

Click here to get full coverage on Nurix Therapeutics (NRIX) Stock Falls After Q3 Earnings Miss - GuruFocus

Nurix Therapeutics (NRIX) Stock Falls After Q3 Earnings Miss  GuruFocus

Nurix Therapeutics (NRIX) Stock Falls After Q3 Earnings Miss - GuruFocus

Click here to get full coverage on Wells Fargo Raises Price Target for Nurix Therapeutics (NRIX) to $30 | NRIX Stock News - GuruFocus

Wells Fargo Raises Price Target for Nurix Therapeutics (NRIX) to $30 | NRIX Stock News  GuruFocus

Wells Fargo Raises Price Target for Nurix Therapeutics (NRIX) to $30 | NRIX Stock News - GuruFocus

Click here to get full coverage on Nurix Therapeutics Could Disrupt BTK Therapy And Reward Investors (NASDAQ:NRIX) - Seeking Alpha

Nurix Therapeutics Could Disrupt BTK Therapy And Reward Investors (NASDAQ:NRIX)  Seeking Alpha

Nurix Therapeutics Could Disrupt BTK Therapy And Reward Investors (NASDAQ:NRIX) - Seeking Alpha

Click here to get full coverage on NRIX: Net loss widened to $264.5M on $84M revenue, with $592.9M in cash and strong R&D investment - TradingView

NRIX: Net loss widened to $264.5M on $84M revenue, with $592.9M in cash and strong R&D investment  TradingView

NRIX: Net loss widened to $264.5M on $84M revenue, with $592.9M in cash and strong R&D investment - TradingView

Click here to get full coverage on Piper Sandler Raises Price Target on Nurix Therapeutics (NRIX) t - GuruFocus

Piper Sandler Raises Price Target on Nurix Therapeutics (NRIX) t  GuruFocus

Piper Sandler Raises Price Target on Nurix Therapeutics (NRIX) t - GuruFocus

Click here to get full coverage on NRIX: Stifel Raises Price Target to $35, Maintains 'Buy' Rating - GuruFocus

NRIX: Stifel Raises Price Target to $35, Maintains 'Buy' Rating  GuruFocus

NRIX: Stifel Raises Price Target to $35, Maintains 'Buy' Rating - GuruFocus

Click here to get full coverage on Behavioral Patterns of NRIX and Institutional Flows - Stock Traders Daily

Behavioral Patterns of NRIX and Institutional Flows  Stock Traders Daily

Behavioral Patterns of NRIX and Institutional Flows - Stock Traders Daily

Click here to get full coverage on NRIX: RBC Capital Raises Price Target and Maintains Outperform R - GuruFocus

NRIX: RBC Capital Raises Price Target and Maintains Outperform R  GuruFocus

NRIX: RBC Capital Raises Price Target and Maintains Outperform R - GuruFocus

Click here to get full coverage on Nurix Therapeutics (NRIX) Prices Stock Offering to Fund Drug Dev - GuruFocus

Nurix Therapeutics (NRIX) Prices Stock Offering to Fund Drug Dev  GuruFocus

Nurix Therapeutics (NRIX) Prices Stock Offering to Fund Drug Dev - GuruFocus

Click here to get full coverage on NRIX: Wells Fargo Lowers Price Target to $29, Maintains Overweig - GuruFocus

NRIX: Wells Fargo Lowers Price Target to $29, Maintains Overweig  GuruFocus

NRIX: Wells Fargo Lowers Price Target to $29, Maintains Overweig - GuruFocus

Click here to get full coverage on Nurix (NRIX) Achieves Key Milestone with Q4 Revenue and Program Launch - GuruFocus

Nurix (NRIX) Achieves Key Milestone with Q4 Revenue and Program Launch  GuruFocus

Nurix (NRIX) Achieves Key Milestone with Q4 Revenue and Program Launch - GuruFocus

Click here to get full coverage on H.C. Wainwright Remains a Buy on Nurix Therapeutics (NRIX) - Insider Monkey

H.C. Wainwright Remains a Buy on Nurix Therapeutics (NRIX)  Insider Monkey

H.C. Wainwright Remains a Buy on Nurix Therapeutics (NRIX) - Insider Monkey

Click here to get full coverage on Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock - Yahoo Finance

Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock  Yahoo Finance

Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock - Yahoo Finance

Click here to get full coverage on Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update - Investing News Network

Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update  Investing News Network

NRIX

Price Chart

Key Statistics

Technicals

About NRIX

Latest News

Ring, chief legal officer, sells Nurix (NRIX) shares for $125,792 - Investing.com

Handelsbanken Fonder AB Buys 240,000 Shares of Nurix Therapeutics, Inc. $NRIX - MarketBeat

Nurix Therapeutics (NRIX) Valuation Check After Recent Share Price Volatility And Rich Price To Sales Multiple - Yahoo Finance

Advanced Charts

Top Gainers

Top Losers